

14th International Congress on Antiphospholipid Antibodies
antiphospholipid syndrome laboratory diagnostics and

Autoimmunity Reviews

13, 917-930

DOI: [10.1016/j.autrev.2014.05.001](https://doi.org/10.1016/j.autrev.2014.05.001)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Antiphospholipid Antibody Syndrome. , 0, , 305-316.		0
2	Stroke as a Complication of General Medical Disorders. , 2014, , 199-220.		0
3	Hypercoagulability in celiac disease – An update. Autoimmunity Reviews, 2014, 13, 1138-1141.	5.8	33
4	Clinical utility of automated chemiluminescent antiphospholipid antibody assay. Thrombosis Research, 2015, 136, 1033-1039.	1.7	10
5	Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS. BMC Biotechnology, 2015, 15, 104.	3.3	8
6	Update on the pathogenesis and treatment of the antiphospholipid syndrome. Current Opinion in Rheumatology, 2015, 27, 476-482.	4.3	35
7	Release of Neutrophil Extracellular Traps by Neutrophils Stimulated With Antiphospholipid Antibodies: A Newly Identified Mechanism of Thrombosis in the Antiphospholipid Syndrome. Arthritis and Rheumatology, 2015, 67, 2990-3003.	5.6	283
8	Laboratory Methodology Important in the Diagnosis and Prognosis of Antiphospholipid Syndrome. , 2015, , .		1
9	Antiphospholipid antibodies in patients with upper-extremity deep vein thrombosis. Central-European Journal of Immunology, 2015, 3, 307-310.	1.2	4
10	–New–Antigenic Targets and Methodological Approaches for Refining Laboratory Diagnosis of Antiphospholipid Syndrome. Journal of Immunology Research, 2015, 2015, 1-13.	2.2	42
11	Antiphospholipid Antibodies and Antiphospholipid Syndrome during Pregnancy: Diagnostic Concepts. Frontiers in Immunology, 2015, 6, 205.	4.8	25
12	Antibodies to domain I of β 2-glycoprotein I and IgA antiphospholipid antibodies in patients with –seronegative– antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2015, 74, 317-319.	0.9	42
13	Preeclampsia: Reflections on How to Counsel About Preventing Recurrence. Journal of Obstetrics and Gynaecology Canada, 2015, 37, 887-893.	0.7	9
14	Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmunity Reviews, 2015, 14, 358-362.	5.8	101
15	Autoantibodies 2015: From diagnostic biomarkers toward prediction, prognosis and prevention. Autoimmunity Reviews, 2015, 14, 555-563.	5.8	76
16	Antiphospholipid syndrome: antibodies to Domain 1 of β 2-glycoprotein 1 correctly classify patients at risk. Journal of Thrombosis and Haemostasis, 2015, 13, 782-787.	3.8	113
17	The relevance of –non-criteria– clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmunity Reviews, 2015, 14, 401-414.	5.8	194
18	Current treatment of antiphospholipid syndrome: lights and shadows. Nature Reviews Rheumatology, 2015, 11, 586-596.	8.0	93

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2015, 14, 680-685.	5.8	58
20	Purified IgG from Patients with Obstetric but not IgG from Non-Obstetric Antiphospholipid Syndrome Inhibit Trophoblast Invasion. <i>American Journal of Reproductive Immunology</i> , 2015, 73, 390-401.	1.2	35
21	The emerging role of multiple antiphospholipid antibodies positivity in patients with antiphospholipid syndrome. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1255-1263.	3.0	10
22	Antiphospholipid Syndrome and the Kidney. <i>Seminars in Nephrology</i> , 2015, 35, 478-486.	1.6	66
23	The Role of the Gut Microbiota in the Pathogenesis of Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2015, 17, 472.	4.7	32
24	A Clinical Approach for Defining the Threshold between Low and Medium Anti-Cardiolipin Antibody Levels for QUANTA Flash Assays. <i>Antibodies</i> , 2016, 5, 14.	2.5	10
25	The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. <i>European Journal of Rheumatology</i> , 2016, 3, 75-84.	0.6	141
26	Recent advances in understanding antiphospholipid syndrome. <i>F1000Research</i> , 2016, 5, 2908.	1.6	12
27	Antiphospholipid Antibodies: Their Origin and Development. <i>Antibodies</i> , 2016, 5, 15.	2.5	12
28	The Significance of Anti-Beta-2-Glycoprotein I Antibodies in Antiphospholipid Syndrome. <i>Antibodies</i> , 2016, 5, 16.	2.5	27
29	Antiphospholipid Syndrome and Kidney Involvement: New Insights. <i>Antibodies</i> , 2016, 5, 17.	2.5	9
30	Measuring IgA Anti- β 2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. <i>PLoS ONE</i> , 2016, 11, e0156407.	2.5	66
31	Hypercoagulability in Kidney Transplant Recipients. <i>Transplantation</i> , 2016, 100, 719-726.	1.0	40
32	Treatment of catastrophic antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2016, 28, 218-227.	4.3	82
33	Role of anti-domain 1 β 2-glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1779-1787.	3.8	72
34	Proinflammatory proteins in female and male patients with primary antiphospholipid syndrome: preliminary data. <i>Clinical Rheumatology</i> , 2016, 35, 2477-2483.	2.2	11
35	Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome. <i>Scientific Reports</i> , 2016, 6, 23839.	3.3	23
36	Evaluation of antiphospholipid antibody assays using latent class analysis to address the lack of a reference standard. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1929-1937.	2.3	2

#	ARTICLE	IF	CITATIONS
37	Antiphospholipid syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 133-148.	3.3	48
38	The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome. <i>Clinical Rheumatology</i> , 2016, 35, 1361-1365.	2.2	13
39	Autoantibodies and Biomarkers: Diagnostic Aspects. <i>Rare Diseases of the Immune System</i> , 2016, , 47-59.	0.1	0
40	Pregnancy in women with systemic lupus erythematosus (SLE). <i>European Journal of Internal Medicine</i> , 2016, 32, 7-12.	2.2	64
41	TNF-alpha and annexin A2: inflammation in thrombotic primary antiphospholipid syndrome. <i>Rheumatology International</i> , 2016, 36, 1649-1656.	3.0	16
42	Evaluation of three fully automated immunoassay systems for detection of IgA anti-β ₂ glycoprotein I antibodies. <i>International Journal of Laboratory Hematology</i> , 2016, 38, 560-568.	1.3	25
43	APS - Diagnostics and challenges for the future. <i>Autoimmunity Reviews</i> , 2016, 15, 1031-1033.	5.8	29
44	Diagnosis of antiphospholipid syndrome: From an historical perspective to the emergence of new autoantibodies. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 555-560.	0.2	1
45	Association of anticardiolipin, antiphosphatidylserine, anti-β ₂ glycoprotein I, and antiphosphatidylcholine autoantibodies with canine immune thrombocytopenia. <i>BMC Veterinary Research</i> , 2016, 12, 106.	1.9	2
46	Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay. <i>Clinical and Molecular Allergy</i> , 2016, 14, 6.	1.8	37
47	Double positivity of the IgG isotype of both anticardiolipin and anti-β ₂ glycoprotein I antibodies is associated with the highest number of vascular impairment parameters in patients with primary antiphospholipid syndrome: preliminary data. <i>Clinical Rheumatology</i> , 2016, 35, 2947-2954.	2.2	4
48	Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. <i>Arthritis Research and Therapy</i> , 2016, 18, 111.	3.5	32
49	The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 552-557.	2.1	20
50	Recognition and management of antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2016, 28, 51-59.	4.3	23
51	The challenges of lupus anticoagulants. <i>Expert Review of Hematology</i> , 2016, 9, 389-400.	2.2	31
52	Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2016, 15, 203-209.	5.8	50
53	The hidden world of anti-phospholipid antibodies and female infertility: A literature appraisal. <i>Autoimmunity Reviews</i> , 2016, 15, 493-500.	5.8	31
54	Antiphospholipid Antibody Syndrome With Valvular Vegetations in Acute Q Fever. <i>Clinical Infectious Diseases</i> , 2016, 62, 537-544.	5.8	33

#	ARTICLE	IF	CITATIONS
56	Delineating the deranged immune system in the antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2016, 15, 50-60.	5.8	56
57	Antiphospholipid syndrome presenting as cerebral venous sinus thrombosis: a case series and a review: Table A1. <i>Journal of Clinical Pathology</i> , 2016, 69, 337-343.	2.0	13
58	Antiphospholipid Antibodies and Renal Impairment Parameters in Diabetic Nephropathy: Preliminary Data. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 379-383.	1.7	4
59	Diagnostic value of antibodies to phosphatidylserine/prothrombin complex for antiphospholipid syndrome in Chinese patients. <i>Clinical Rheumatology</i> , 2017, 36, 401-406.	2.2	16
60	History, Classification, and Subsets of the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, , 1-16.	0.1	3
61	Laboratory Markers With Clinical Significance in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 47-69.	0.1	0
62	Síndrome antifosfolípido. <i>Medicine</i> , 2017, 12, 1551-1559.	0.0	0
63	Parestesias y cefalea en mujer de 39 años. <i>Medicine</i> , 2017, 12, 1614.e1-1614.e4.	0.0	0
64	Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome—Biomarkers of the Disease and Biopharmaceuticals. <i>Current Rheumatology Reports</i> , 2017, 19, 40.	4.7	4
65	Antiphospholipid antibodies negativization: time for testing for non-criteria aPL?. <i>Lupus</i> , 2017, 26, 1457-1458.	1.6	6
66	Antiphospholipid syndrome: an update for clinicians and scientists. <i>Current Opinion in Rheumatology</i> , 2017, 29, 458-466.	4.3	18
67	Coexistence of anti- β_2 -glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies suggests strong thrombotic risk. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 882-889.	2.3	13
68	Antiphospholipid Antibodies and Atherosclerosis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 193-214.	0.1	0
69	Detrimental roles of TNF-alpha in the antiphospholipid syndrome and de novo synthesis of antiphospholipid antibodies induced by biopharmaceuticals against TNF-alpha. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 565-570.	2.1	7
70	Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconversion?. <i>Autoimmunity Reviews</i> , 2017, 16, 1109-1114.	5.8	19
71	Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances. <i>Nature Reviews Rheumatology</i> , 2017, 13, 548-560.	8.0	153
72	Solid Phase Immunoassay for the Detection of Anticardiolipin Antibodies. <i>Methods in Molecular Biology</i> , 2017, 1646, 185-199.	0.9	5
73	Solid Phase Immunoassay for the Detection of Anti- β_2 Glycoprotein I Antibodies. <i>Methods in Molecular Biology</i> , 2017, 1646, 201-215.	0.9	4

#	ARTICLE	IF	CITATIONS
74	Antiphospholipid antibody syndrome. JAAPA: Official Journal of the American Academy of Physician Assistants, 2017, 30, 10-14.	0.3	15
75	Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies. Autoimmunity Highlights, 2017, 8, 5.	3.9	6
76	A unique antiphospholipid assay recognizing phospholipid mixture compared with criteria antiphospholipid immunoassays in lupus patients. Lupus, 2017, 26, 606-615.	1.6	6
77	Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. Lupus, 2017, 26, 266-276.	1.6	53
78	Immunotherapeutic strategies in antiphospholipid syndrome. Internal Medicine Journal, 2017, 47, 250-256.	0.8	4
79	In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis. Arthritis and Rheumatology, 2017, 69, 655-667.	5.6	166
80	Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up. Clinical Reviews in Allergy and Immunology, 2017, 53, 14-27.	6.5	22
81	Update on antiphospholipid antibody syndrome. Revista Da Associação Médica Brasileira, 2017, 63, 994-999.	0.7	22
82	Dimerized Domain V of Beta2-Glycoprotein I Is Sufficient to Upregulate Procoagulant Activity in PMA-Treated U937 Monocytes and Require Intact Residues in Two Phospholipid-Binding Loops. Antibodies, 2017, 6, 8.	2.5	8
83	Nephropathy in Pparg-null mice highlights PPAR β systemic activities in metabolism and in the immune system. PLoS ONE, 2017, 12, e0171474.	2.5	34
84	Incidence of thromboembolic events in asymptomatic carriers of IgA anti β 2 glycoprotein-I antibodies. PLoS ONE, 2017, 12, e0178889.	2.5	54
85	Oxidation of β 2-glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. PLoS ONE, 2017, 12, e0186513.	2.5	8
86	Identifying Additional Risk Factors for Thrombosis and Pregnancy Morbidities Among Antiphospholipid Antibodies Carriers. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 980-985.	1.7	6
87	Antiphospholipid syndrome, "the best prophet of the future". Modern Rheumatology, 2018, 28, 409-416.	1.8	17
88	Antiphospholipid syndrome. Nature Reviews Disease Primers, 2018, 4, 17103.	30.5	233
90	Diagnostic laboratory tests for systemic autoimmune rheumatic diseases: unmet needs towards harmonization. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1743-1748.	2.3	22
91	Neutrophils and redox stress in the pathogenesis of autoimmune disease. Free Radical Biology and Medicine, 2018, 125, 25-35.	2.9	115
92	Update on Antiphospholipid Syndrome: Ten Topics in 2017. Current Rheumatology Reports, 2018, 20, 15.	4.7	22

#	ARTICLE	IF	CITATIONS
93	Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 939-946.	2.3	15
94	Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin. <i>American Journal of Clinical Pathology</i> , 2018, 149, 401-411.	0.7	9
95	Lupus anticoagulant testing using two parallel methods detects additional cases and predicts persistent positivity. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1289-1296.	2.3	10
96	Laboratory Diagnostics of Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 439-444.	2.7	23
98	Clinical characteristics and thrombosis outcomes of paediatric antiphospholipid syndrome: analysis of 58 patients. <i>Clinical Rheumatology</i> , 2018, 37, 1295-1303.	2.2	35
99	The Significance of Antibodies against Domain I of Beta-2 Glycoprotein I in Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 458-465.	2.7	12
100	IgA anti- β 2 glycoprotein I antibodies: Experience from a large center. <i>Thrombosis Research</i> , 2018, 162, 38-43.	1.7	17
101	Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 614-624.	2.3	77
102	Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). <i>Modern Rheumatology</i> , 2018, 28, 642-648.	1.8	16
103	Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study. <i>Rheumatology International</i> , 2018, 38, 229-238.	3.0	2
104	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000785.	3.8	38
105	Laboratory diagnosis of antiphospholipid syndrome. <i>Frontiers in Laboratory Medicine</i> , 2018, 2, 97-101.	1.7	2
106	Obstetric antiphospholipid syndrome. <i>Lupus Science and Medicine</i> , 2018, 5, e000197.	2.7	42
107	The clinical value of assays detecting antibodies against domain I of β 2-glycoprotein I in the antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018, 17, 1210-1218.	5.8	27
108	Autoimmune, rheumatic, chronic inflammatory diseases: Neutrophil extracellular traps on parade. <i>Autoimmunity</i> , 2018, 51, 281-287.	2.6	19
109	Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I. <i>Frontiers in Immunology</i> , 2018, 9, 2244.	4.8	11
110	Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. <i>Clinical and Experimental Immunology</i> , 2018, 194, 27-38.	2.6	16
111	Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?. <i>Current Rheumatology Reports</i> , 2018, 20, 66.	4.7	16

#	ARTICLE	IF	CITATIONS
112	Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases. <i>Autoimmunity Highlights</i> , 2018, 9, 6.	3.9	18
113	Revisiting the Phadia/EliA cut-off values for anticardiolipin and anti-β ₂ -glycoprotein I antibodies: a systematic evaluation according to the guidelines. <i>Lupus</i> , 2018, 27, 1446-1454.	1.6	6
114	Anti-annexin A5 antibodies and 25-hydroxy-cholecalciferol in female patients with primary antiphospholipid syndrome. <i>Clinical Rheumatology</i> , 2018, 37, 3359-3364.	2.2	2
115	Risk Factors for Adverse Maternal and Fetal Outcomes in Women With Confirmed aPL Positivity: Results From a Multicenter Study of 283 Pregnancies. <i>Frontiers in Immunology</i> , 2018, 9, 864.	4.8	34
116	Thrombotic risk assessment and analytical performance of the chemiluminescent analyzer IDS-iSYS for the detection of anti-cardiolipin and anti-beta 2 glycoprotein I autoantibodies. <i>Clinical Immunology</i> , 2018, 194, 92-99.	3.2	6
117	<i>Immunology and Reproduction</i> , 2019, , 301-321.e3.		6
118	Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies. <i>Frontiers in Immunology</i> , 2019, 10, 1948.	4.8	33
120	Does seronegative obstetric APS exist? –pro– and –consâ€. <i>Autoimmunity Reviews</i> , 2019, 18, 102407.	5.8	21
121	Prevalence of Antiphospholipid Antibodies Negativisation in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Multicentre Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1920-1926.	3.4	13
122	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. <i>Thrombosis Research</i> , 2019, 175, 32-36.	1.7	13
123	Adiponectin: a therapeutic target in the antiphospholipid syndrome?. <i>Rheumatology International</i> , 2019, 39, 1519-1525.	3.0	2
124	Anti-domain 1 of beta2-glycoprotein I aids risk stratification in lupus anticoagulant-positive patients. <i>Clinical and Experimental Medicine</i> , 2019, 19, 339-345.	3.6	6
126	IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. <i>Thrombosis Research</i> , 2019, 177, 157-160.	1.7	30
127	Laboratory Evaluation of Antiphospholipid Syndrome. <i>Clinics in Laboratory Medicine</i> , 2019, 39, 553-565.	1.4	6
128	An Approach to Retiform Purpura for the Inpatient Dermatologist. <i>Current Dermatology Reports</i> , 2019, 8, 245-257.	2.1	1
129	Antiphospholipid Antibody Syndrome: Pathogenesis, Diagnosis, and Management in Pregnancy. <i>Maternal-Fetal Medicine</i> , 2019, 1, 38-42.	0.8	5
130	Pathogenesis of Antiphospholipid Antibody Syndrome. , 2019, , 324-337.		3
131	Clinical Aspects of Antiphospholipid Syndrome. , 2019, , 532-542.		0

#	ARTICLE	IF	CITATIONS
132	Role of NOD2 in antiphospholipid antibody-induced and bacterial MDP amplification of trophoblast inflammation. <i>Journal of Autoimmunity</i> , 2019, 98, 103-112.	6.5	12
133	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 93-106.	5.8	101
134	Laboratory Diagnosis of Lupus Anticoagulant and Antiphospholipid Antibodies. , 2019, , 925-931.		0
135	Thrombophilia. , 2019, , 242-265.		2
136	Recomendaciones de la Sociedad Española de Reumatología sobre síndrome antifosfolípido primario. Parte I: Diagnóstico, evaluación y tratamiento. <i>Reumatología Clínica</i> , 2020, 16, 71-86.	0.5	10
137	Antiphospholipid Antibodies in Patients With Lupus Anticoagulant Prozone Effect. <i>American Journal of Clinical Pathology</i> , 2020, 153, 229-234.	0.7	4
138	The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. <i>Blood Reviews</i> , 2020, 39, 100610.	5.7	85
139	Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?. <i>Rheumatology</i> , 2020, 59, 146-152.	1.9	14
141	Anti-phospholipid antibody prevalence and association with subclinical atherosclerosis and atherothrombosis in the general population. <i>International Journal of Cardiology</i> , 2020, 300, 209-213.	1.7	15
142	Recommendations of the Spanish Rheumatology Society for primary antiphospholipid syndrome. Part I: Diagnosis, evaluation and treatment. <i>Reumatología Clínica (English Edition)</i> , 2020, 16, 71-86.	0.3	0
143	Detection of anti-β ₂ glycoprotein I antibodies by chemiluminescence enables the identification of high-risk antiphospholipid syndrome patients: A multicenter multiplatform study. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 463-478.	3.8	20
144	The Weight of IgA Anti-β ₂ glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8972.	4.1	23
145	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1490-1501.	3.4	60
146	A glimpse into the history of description of the antiphospholipid syndrome. <i>Lupus</i> , 2020, 29, 1493-1502.	1.6	0
147	Immunoglobulin A Isotype of Antiphospholipid Antibodies Does Not Provide Added Value for the Diagnosis of Antiphospholipid Syndrome in a Chinese Population. <i>Frontiers in Immunology</i> , 2020, 11, 568503.	4.8	9
148	Recurrent nonbacterial thrombotic endocarditis and stroke on anticoagulation. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2020, 10, 466-469.	0.8	6
149	High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients. <i>Lupus</i> , 2020, 29, 1412-1422.	1.6	4
150	NETs in APS: Current Knowledge and Future Perspectives. <i>Current Rheumatology Reports</i> , 2020, 22, 67.	4.7	31

#	ARTICLE	IF	CITATIONS
151	Coagulopathy of COVID-19 and antiphospholipid antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, .	3.8	72
152	MK2 Is Required for Neutrophil-Derived ROS Production and Inflammatory Bowel Disease. <i>Frontiers in Medicine</i> , 2020, 7, 207.	2.6	33
153	Elevated IgA antiphospholipid antibodies in healthy pregnant women in Sudan but not Sweden, without corresponding increase in IgA anti-β ₂ glycoprotein I domain 1 antibodies. <i>Lupus</i> , 2020, 29, 463-473.	1.6	6
154	Clinical performance of automated chemiluminescent methods for anticardiolipin and anti-β ₂ glycoprotein I antibodies detection in a large cohort of Chinese patients with antiphospholipid syndrome. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 206-213.	1.3	4
155	Antiphospholipid syndrome: a clinical perspective. <i>Chinese Medical Journal</i> , 2020, 133, 929-940.	2.3	22
156	Antibodies and diagnostic tests in antiphospholipid syndrome. , 2021, , 565-574.		1
157	Reality Check on Antiphospholipid Antibodies in COVID-19-Associated Coagulopathy. <i>Arthritis and Rheumatology</i> , 2021, 73, 173-174.	5.6	39
158	Insight into the hypercoagulable state of high-risk thrombotic APS patients: Contribution of anti-β ₂ GPI and aPS/PT antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 805-813.	3.8	15
159	Role of Autoantibodies in Infertility, Miscarriage, and Assisted Reproductive Technology Outcomes. <i>Reproductive and Developmental Medicine</i> , 2021, 5, 161-173.	0.5	2
160	Stroke as a Complication of General Medical Disorders. , 2021, , 171-187.		0
161	Antineutrophil properties of natural gingerols in models of lupus. <i>JCI Insight</i> , 2021, 6, .	5.0	19
162	Prognostic analysis of antibody typing and treatment for antiphospholipid syndrome-related recurrent spontaneous abortion. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 156, 107-111.	2.3	3
163	Síndrome antifosfolípido. <i>Medicine</i> , 2021, 13, 1760-1768.	0.0	0
164	Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE. <i>Lupus</i> , 2021, 30, 1289-1299.	1.6	6
165	Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy—a tertiary centre experience in an Appalachian state. <i>Lupus Science and Medicine</i> , 2021, 8, e000467.	2.7	4
166	Antiphospholipid antibodies in patients with Graves' orbitopathy: preliminary data. <i>Endocrine</i> , 2021, 74, 349-354.	2.3	2
167	Anti-beta 2 glycoprotein 1 domain IgA positive antiphospholipid syndrome secondary to incomplete Behçet's disease: a case report. <i>Annals of Palliative Medicine</i> , 2021, 10, 7114-7120.	1.2	1
168	Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies. <i>Biomedicine</i> , 2021, 9, 671.	3.2	17

#	ARTICLE	IF	CITATIONS
169	Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?. <i>Current Rheumatology Reports</i> , 2021, 23, 65.	4.7	29
170	Antiphospholipid antibodies and COVID-19 thrombotic vasculopathy: one swallow does not make a summer. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1105-1107.	0.9	12
171	Antiphospholipid Antibody Assays in 2021: Looking for a Predictive Value in Addition to a Diagnostic One. <i>Frontiers in Immunology</i> , 2021, 12, 726820.	4.8	21
172	Evaluation of the Diagnostic Value of Non-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort. <i>Frontiers in Immunology</i> , 2021, 12, 741369.	4.8	10
173	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Classification Report. , 2017, , 279-290.		4
174	Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis. , 2017, , 77-116.		3
175	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests. , 2017, , 171-187.		3
176	Antibody profiles comprising anti phosphatidylserine/prothrombin differently affect thrombin generation and protein C resistance in antiphospholipid antibody carriers. <i>Clinica Chimica Acta</i> , 2020, 510, 796-801.	1.1	7
177	Endoplasmic reticulum stress occurs in association with the extrusion of toxic extracellular vesicles from human placentae treated with antiphospholipid antibodies. <i>Clinical Science</i> , 2020, 134, 459-472.	4.3	13
178	Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1220-1227.	3.4	27
179	Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target. <i>JCI Insight</i> , 2017, 2, .	5.0	75
180	Primary Antiphospholipid Antibody Syndrome Complicated with Cerebellar Hemorrhage and Aortic Dissection: A Case Report. <i>American Journal of Case Reports</i> , 2019, 20, 1852-1856.	0.8	4
181	Patterns and Appropriateness of Thrombophilia Testing in an Academic Medical Center. <i>Journal of Hospital Medicine</i> , 2017, 12, 705-709.	1.4	18
182	Antiphosphatidylethanolamine Antibodies and Deep Vein Thrombosis in Lupus Patients with Antiphospholipid Syndrome. <i>Romanian Journal of Laboratory Medicine</i> , 2018, 26, 243-250.	0.2	3
183	OUP accepted manuscript. <i>journal of applied laboratory medicine</i> , The, 2022, 7, 373-378.	1.3	0
185	Antiphosphatidylethanolamine Antibodies: New Pieces to the Puzzle of the Antiphospholipid Syndrome?. <i>Journal of Arthritis</i> , 2015, 04, .	0.3	0
186	Diagnosing Antiphospholipid Antibody Syndrome: A Review of the Criterion for Definite APS. <i>The Open Urology & Nephrology Journal</i> , 2015, 8, 18-21.	0.2	0
187	Current practices for lupus anticoagulant testing at a tertiary care hospital and impact on laboratory resources. <i>Annals of Saudi Medicine</i> , 2015, 35, 383-386.	1.1	0

#	ARTICLE	IF	CITATIONS
188	Antibodies and Diagnostic Tests in Antiphospholipid Syndrome. , 2016, , 495-501.		0
189	The Impact of aPL Detection on Pregnancy. Rare Diseases of the Immune System, 2016, , 169-181.	0.1	0
190	Definition and Epidemiology of Antiphospholipid Syndrome. , 2017, , 147-169.		1
191	Antiphospholipid Syndrome: What Should Patients Know?. , 2017, , 341-357.		1
192	Efficacy and tolerance of selective and non-selective factor Xa inhibitors in the prevention of thrombosis in kidney disease in patients with systemic lupus erythematosus and antiphospholipid syndrome. Sovremennaya Revmatologiya, 2019, 13, 26-34.	0.5	0
194	Antiphospholipid syndrome – a life threatening condition. Romanian Journal of Laboratory Medicine, 2019, 27, 333-337.	0.2	0
195	Rheumatologic and Autoimmune Emergencies. , 2019, , 363-366.		0
196	SÃndrome antifosfolÃpido. FMC Formacion Medica Continuada En Atencion Primaria, 2020, 27, 81-87.	0.0	0
197	Defibrotide Inhibits Antiphospholipid Antibody-Mediated Neutrophil Extracellular Trap Formation and Venous Thrombosis. Arthritis and Rheumatology, 2022, 74, 902-907.	5.6	19
198	Avidity of anti-phospholipid antibodies in relation to their levels. Central-European Journal of Immunology, 2020, 45, 136-143.	1.2	1
199	Antiphospholipid Antibodies Increase Endometrial Stromal Cell Decidualization, Senescence, and Inflammation via Toll-like Receptor 4, Reactive Oxygen Species, and p38 MAPK Signaling. Arthritis and Rheumatology, 2022, 74, 1001-1012.	5.6	11
200	Antiphospholipid Antibodies in Healthy Serbian Middle-Aged Subjects: Preliminary Data. Journal of Medical Biochemistry, 0, , .	1.7	0
201	Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. Seminars in Immunopathology, 2022, 44, 347-362.	6.1	67
202	Additional risk factors associated with thrombosis and pregnancy morbidity in a unique cohort of antiphospholipid antibody-positive patients. Chinese Medical Journal, 2022, 135, 658-664.	2.3	8
203	A Simplified Understanding of the Black Swan: Anti-phospholipid Antibody Syndrome. Journal of the Nepal Medical Association, 2019, 57, 133-145.	0.4	0
205	Evidence of Thrombogenesis Recurrence Induced by IgA Antiphospholipid Antibody Î2 Glycoprotein I-Dependent in Early Adulthood. Cureus, 2022, 14, e23535.	0.5	0
206	An Update on Antiphospholipid Syndrome. Current Rheumatology Reports, 2021, 23, 84.	4.7	20
208	Solid Phase Assays for Antiphospholipid Antibodies. Seminars in Thrombosis and Hemostasis, 2022, 48, 661-671.	2.7	11

#	ARTICLE	IF	CITATIONS
209	Hematological manifestations of antiphospholipid syndrome: Going beyond thrombosis. <i>Blood Reviews</i> , 2023, 58, 101015.	5.7	5
211	Antiphosphatidylserine/prothrombin antibodies (aPS/PT) and risk of obstetric anti-phospholipid syndrome. <i>American Journal of Reproductive Immunology</i> , 2023, 89, .	1.2	1
212	Non-bacterial thrombotic endocarditis: A state-of-the-art contemporary review. <i>Progress in Cardiovascular Diseases</i> , 2022, 74, 99-110.	3.1	10
213	Advances in the Pathophysiology of Thrombosis in Antiphospholipid Syndrome: Molecular Mechanisms and Signaling through Lipid Rafts. <i>Journal of Clinical Medicine</i> , 2023, 12, 891.	2.4	3
214	Extra-criteria antiphospholipid antibodies in patients with small vessel brain lesions and clinical manifestations associated with antiphospholipid syndrome. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2023, 32, 107034.	1.6	1
215	Moonlighting chromatin: when DNA escapes nuclear control. <i>Cell Death and Differentiation</i> , 2023, 30, 861-875.	11.2	8
216	Humoral immunity and thrombosis in COVID-19. , 2023, , 375-392.		0
217	Carotid Artery Thrombus in Antiphospholipid Antibody Syndrome. <i>Radiology</i> , 0, , .	7.3	0
218	Prevalence of Antiphospholipid Antibodies and Association With Incident Cardiovascular Events. <i>JAMA Network Open</i> , 2023, 6, e236530.	5.9	5
220	Prevalence and adverse consequences of delayed diagnosis and misdiagnosis in thrombotic antiphospholipid syndrome. An observational cohort study and a review of the literature. <i>Clinical Rheumatology</i> , 0, , .	2.2	0
221	Cryptogenic stroke. Part 4: Antiphospholipid syndrome and cancer. <i>Meditinskiy Sovet</i> , 2023, , 21-31.	0.5	0
222	Catastrophic Antiphospholipid Syndrome: A Complex Diagnosis in the Setting of Lupus. <i>Cureus</i> , 2023, , .	0.5	0
223	Non-criteria autoantibodies in antiphospholipid syndrome may be associated with underlying disease activity. <i>Irish Journal of Medical Science</i> , 0, , .	1.5	0
224	Beyond the classics: The emerging value of anti-phosphatidylserine/prothrombin antibodies in antiphospholipid syndrome. <i>Clinical Immunology</i> , 2023, 256, 109804.	3.2	0